Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 May 2019 | Story Ruan Bruwer | Photo Zimbio
Simoné Gouws
Simoné Gouws (right) in action for the Protea hockey team last year. The defender will be a key player for the Kovsie team in the Varsity hockey competition.

The coach of the first women’s hockey team of the University of the Free State is confident that they can do well in the upcoming Varsity hockey tournament.

The competition works on a gender-rotation system every year. This will be the fourth term of Varsity hockey for women. The Kovsie women has a good record. In 2013 they ended fourth, in 2015 they were second, and in 2017 fifth.

The Kovsies will be facing the University of Johannesburg (UJ) on Friday 3 May 2019. On Saturday, the Maties is lying in wait and the North-West University on Sunday.

“I am confident that we will be doing well. If each player plays her role very well, we should reach the semi-final stage. We have put in the hard work, with good progress. We have played three matches so far in 2019 and haven’t been on the losing side yet,” said Luke Makeleni, head coach.

In friendlies last month, the Kovsies drew to NWU (0-0), defeated UJ by 3-1, and had a good win (6-0) against the Johannesburg club, Shumbas.

“We have quite an experienced squad, with seven survivors from the previous Varsity hockey competition (in 2017), so they know what is expected,” Makeleni said. He is in his third year of coaching the women.

The Kovsies have several players with national experience. Simoné Gouws made her debut for the Proteas last year. Casey-Jean Botha, Shindré-Lee Simmons, Antonet Louw, and Lizanne Jacobs have all represented the South African U21 team. Botha is also in the Protea squad. 

■ The Kovsie team: Wiané Grobler, Chane Hartel, Mikayla Claassen, Anke Badenhorst, Casey-Jean Botha, Shindré-Lee Simmons, Esté van Schalkwyk, Nadia van Staden, Antonet Louw, Michelle Ngoetjane, Heraldine Olin, Lizanne Jacobs, Refilwe Ralikontsane, Mielanka van Schalkwyk, Nela Mbedu, Simoné Gouws, Frances Louw, Kia-Leigh Erasmus.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept